newsRare melanoma type highly responsive to immunotherapy12 January 2018 | By European Pharmaceutical ReviewMoffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.